Cargando…

Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence

BACKGROUND: Clinicians are required to assimilate, critically evaluate, and extrapolate information to support appropriate use of biosimilars across indications. OBJECTIVES: The objective of this study was to systematically collate all published data in order to assess the weight (quantity and quali...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobs, Ira, Petersel, Danielle, Isakov, Leah, Lula, Sadiq, Lea Sewell, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126192/ https://www.ncbi.nlm.nih.gov/pubmed/27885553 http://dx.doi.org/10.1007/s40259-016-0201-6

Ejemplares similares

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2016)

Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2017)

The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects
por: Declerck, Paul, et al.
Publicado: (2017)

Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future
por: Carrascosa, Jose-Manuel, et al.
Publicado: (2018)

Statistical Primer on Biosimilar Clinical Development
por: Isakov, Leah, et al.
Publicado: (2016)

Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
por: Strand, Vibeke, et al.
Publicado: (2017)

Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review
por: McKinnon, Ross A., et al.
Publicado: (2018)

Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis
por: Simoens, Steven, et al.
Publicado: (2017)

Immunogenicity of biologics in inflammatory bowel disease
por: Vermeire, Séverine, et al.
Publicado: (2018)

Patient attitudes and understanding about biosimilars: an international cross-sectional survey
por: Jacobs, Ira, et al.
Publicado: (2016)

Biosimilars and the extrapolation of indications for inflammatory conditions
por: Tesser, John RP, et al.
Publicado: (2017)

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
por: Cohen, Hillel P., et al.
Publicado: (2022)

The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review
por: Nurmohamed, Michael, et al.
Publicado: (2018)

Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Biosimilars Have Arrived: Rituximab
por: Greenwald, Maria, et al.
Publicado: (2018)

Clinical trials for authorized biosimilars in the European Union: a systematic review
por: Mielke, Johanna, et al.
Publicado: (2016)

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
por: Triantafyllidi, Eleni, et al.
Publicado: (2022)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

An update on the clinical evidence that supports biosimilar approvals in Europe
por: Mielke, Johanna, et al.
Publicado: (2018)

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
por: Cohen, Hillel P., et al.
Publicado: (2018)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
por: Feagan, Brian G., et al.
Publicado: (2018)

Prostate Cancer Diagnosis, Treatment and Outcomes in Patients with Previous or Synchronous Colorectal Cancer: A Systematic Review of Published Evidence
por: Celentano, Giuseppe, et al.
Publicado: (2022)

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
por: Rosen, Lee S., et al.
Publicado: (2017)

Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology
por: Tinsley, Sara M., et al.
Publicado: (2018)

The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies
por: Odinet, Johlee S., et al.
Publicado: (2018)

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
por: Subramanian, Janakiraman, et al.
Publicado: (2017)

A practical guide about biosimilar data for health care providers treating inflammatory diseases
por: Markenson, Joseph, et al.
Publicado: (2017)

Indian Biosimilars and Vaccines at Crossroads–Replicating the Success of Pharmagenerics
por: Panda, Sunita, et al.
Publicado: (2023)

Awake Proning for Nonintubated Adult Hypoxic Patients with COVID-19: A Systematic Review of the Published Evidence
por: Parashar, Samiksha, et al.
Publicado: (2021)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
por: Scheinberg, Morton, et al.
Publicado: (2018)

A systematic review of the quality of reporting in published smoking cessation trials for pregnant women: an explanation for the evidence-practice gap?
por: Bryant, Jamie, et al.
Publicado: (2014)

Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability
por: Zrubka, Zsombor, et al.
Publicado: (2022)

Clinical considerations for the development of biosimilars in oncology
por: Socinski, Mark A, et al.
Publicado: (2015)

Biosimilars in the management of chronic inflammatory diseases: The Dutch experience
por: Müskens, Wieland D., et al.
Publicado: (2019)

Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars
por: Jackisch, Christian, et al.
Publicado: (2017)

Development of biosimilars in an era of oncologic drug shortages
por: Li, Edward, et al.
Publicado: (2015)

Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review
por: Wigfield, Peter, et al.
Publicado: (2019)

Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Retinal Vascular Signs as Screening and Prognostic Factors for Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Current Evidence
por: Aronov, Michael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7cl45soisto3a7nbps323l22mt